84243-58-3

Basic information

• Product Name: IMAZODAN
• Synonyms: 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]pyridazin-3(2H)-one;6-[4-(1H-Imidazole-1-yl)phenyl]-2,3,4,5-tetrahydropyridazine-3-one;Cl 914;6-(4-(1H-imidazol-1-yl)phenyl)-4,5-dihydropyridazin-3(2H)-one;IMAZODAN;CI-914;4,5-DIHYDRO-6-[4-(1H-IMIDAZOL-1-YL)PHENYL]-3(2H)-PYRIDAZINONE;4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone, Cl 914
• CAS NO: 84243-58-3
• Molecular Formula: C₁₃H₁₂N₄O
• Molecular Weight: 240.26058
• Mol File: 84243-58-3.mol
• Article Data: 5

Chemical Properties

• Melting Point: 218℃
• Appearance: yellow, powder/
• Density: 1.34g/cm³
• Refractive Index: 1.696
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO: 50 mg/mL, clear, yellow
• CAS DataBase Reference: IMAZODAN(CAS DataBase Reference)
• NIST Chemistry Reference: IMAZODAN(84243-58-3)
• EPA Substance Registry System: IMAZODAN(84243-58-3)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 84243-58-3(Hazardous Substances Data)

Usage

Uses

Cardiotonic.

InChI:InChI=1/C13H12N4O/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17/h1-4,7-9H,5-6H2,(H,16,18)

Upstream product

• 84243-57-2 4-(1H-imidazol-1-yl)-γ-oxobenzenebutanoic acid 
• 366-77-8 4-(4-fluorophenyl)-4-oxopropionic acid 
• 86798-58-5 α-<4-(1H-imidazol-1-yl)phenyl>-4-morpholineacetonitrile 
• 88427-81-0 4-(1H-imidazol-1-yl)-β-methyl-γ-oxobenzenebutanoic acid 
• 462-06-6 fluorobenzene 

Downstream Products

• 97150-65-7 4-amino-6-<4-(1H-imidazol-1-yl)phenyl>-3(2H)pyridazinone 
• 84243-59-4 6-<4-(1H-imidazole-1-yl)phenyl>-3(2H)-pyridazinone 

Relevant articles and documents

Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones

Substituted 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinone compounds and 6-(substituted)phenyl-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents. Said compounds cause a significant increase in myocardial contractility in the dog. Said compounds also cause a decrease in blood pressure in the spontaneously hypertensive rat. Said compounds are produced by reacting substituted γ-oxobenzenebutanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones which are dehydrogenated to 6-(substituted)phenyl-3(2H)-pyridazinones. Both the intermediate 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones and the 6-(substituted)phenyl-3(2H)-pyridazinones are useful as cardiotonic and antihypertensive agents.

Cardiotonic Agents. 2. Synthesis and Structure-Activity Relationships of 4,5-Dihydro-6--3(2H)-pyridazinones: A New Class of Positive Inotropic Agents

A series of 4,5-dihydro-6--3(2H)-pyridazinones and related compounds were synthesized and evaluated for positive inotropic activity.Most members of this series produced dose-related increases in myocardial contractility that we

Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones

Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)-phenyl]-3(2H)-pyridazinone compounds and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic agents. Said compounds cause a sig